Chapter 7: Analyzes the market by product type, spotlighting segment-specific opportunities and helping stakeholders identify untapped, high-growth areas
While boosting it might be beneficial in some cases, excessively high levels could potentially interfere with other important metabolic processes
Lofton HF, Hold RP, Fielding G, Schwack B, Kaufman L, Oksman Z, et al
Structure Therapeutics is developing GSBR-1290, an oral small molecule GLP-1 agonist that could potentially address the manufacturing scalability challenges facing peptide-based injectablesthe company has noted its current manufacturing capacity could theoretically supply over 120 million patients [46]
In addition to emphasizing traditional strategies such as healthy eating, physical activity, and behavioral support, the new guidelines now encourage physicians to consider prescribing GLP-1 receptor agonistssuch as Ozempic and Wegovyto children as young as 12